Success Metrics

Clinical Success Rate
92.9%

Based on 13 completed trials

Completion Rate
93%(13/14)
Active Trials
0(0%)
Results Posted
62%(8 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_3
4
29%
Ph phase_1
4
29%
Ph phase_2
6
43%

Phase Distribution

4

Early Stage

6

Mid Stage

4

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
4(28.6%)
Phase 2Efficacy & side effects
6(42.9%)
Phase 3Large-scale testing
4(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

92.9%

13 of 14 finished

Non-Completion Rate

7.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(13)
Terminated(1)

Detailed Status

Completed13
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
92.9%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (28.6%)
Phase 26 (42.9%)
Phase 34 (28.6%)

Trials by Status

completed1393%
terminated17%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_3

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

NCT04228783
completedphase_2

A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

NCT03929757
completedphase_2

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

NCT02598388
completedphase_3

A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

NCT04556526
completedphase_2

Partnership for Research on Ebola VACcinations

NCT02876328
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT04228783Phase 3

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Completed
NCT03929757Phase 2

A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

Completed
NCT02598388Phase 2

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Completed
NCT04556526Phase 3

A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

Completed
NCT02876328Phase 2

Partnership for Research on Ebola VACcinations

Completed
NCT02661464Phase 3

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Terminated
NCT05064956Phase 2

Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)

Completed
NCT02509494Phase 3

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo

Completed
NCT02564523Phase 2

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Completed
NCT02416453Phase 2

A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

Completed
NCT02495246Phase 1

A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV

Completed
NCT02860650Phase 1

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

Completed
NCT02376426Phase 1

A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Completed
NCT02376400Phase 1

A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Completed

All 14 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
14